{
    "clinical_study": {
        "@rank": "94227", 
        "arm_group": [
            {
                "arm_group_label": "Lomitapide & Atorvastatin - Taken Together", 
                "arm_group_type": "Experimental", 
                "description": "2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 & Day 15)\n11 single oral doses of atorvastatin (80 mg) (Day 11 through day 21)"
            }, 
            {
                "arm_group_label": "Lomitapide & Atorvastatin - Approx. 12 hours between", 
                "arm_group_type": "Experimental", 
                "description": "2 single oral doses of lomitapide (20 mg) with a 14-day washout between (Day 1 & Day 15)\n11 single oral doses of atorvastatin (80 mg) (Day 12 through day 22)"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to assess the effect of atorvastatin, a weak\n      cytochrome P450 (CYP) 3A4 inhibitor, on the pharmacokinetics (PK) of lomitapide and its 2\n      primary metabolites, M1 and M3."
        }, 
        "brief_title": "Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Effect of Atorvastatin on the Pharmacokinetics of Lomitapide", 
        "detailed_description": {
            "textblock": "This study will be a single center, randomized, open-label, 2-arm study to evaluate the\n      effects of atorvastatin, a weak CYP3A4 inhibitor, on the PK of lomitapide in healthy male\n      and female subjects when atorvastatin is administered simultaneously with lomitapide and\n      when it is administered 12 hours after lomitapide."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy males and females, between 18 and 55 years of age inclusive\n\n          2. BMI between 18.5 and 32.0 kg/m2, inclusive; total body weight of >110 lbs (50 kg);\n\n          3. in good health, determined by no clinically significant or relevant abnormalities\n             identified by a detailed medical history\n\n          4. creatine phosphokinase, AST, and ALT levels must be below 1.5 times the upper limit\n             of normal\n\n          5. clinical laboratory evaluations within the reference range for the test laboratory\n\n          6. negative test for selected drugs of abuse\n\n          7. negative hepatitis panel and negative HIV antibody screens\n\n          8. males will either be sterile or agree to use approved methods of contraception\n\n          9. all females must have a negative serum beta human chorionic gonadotropin pregnancy\n             test and will be required to use a medically acceptable method of contraception.\n\n         10. able to comprehend and willing to sign an Informed Consent Form\n\n        Exclusion Criteria:\n\n          1. significant history or clinical manifestation of any metabolic, allergic,\n             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, GI,\n             neurological, or psychiatric disorder\n\n          2. history of significant hypersensitivity, intolerance, or allergy to any drug\n             compound, food, or other substance\n\n          3. history of stomach or intestinal surgery or resection\n\n          4. history of Gilbert's Syndrome or suspicion of Gilbert's Syndrome\n\n          5. subjects who have an abnormality in the 12-lead ECG\n\n          6. use of any drugs of abuse for 6 months prior to Check-in;\n\n          7. subjects who consume more than 14 units of alcohol per week or who have a significant\n             history of alcoholism or drug/chemical abuse within 1 year prior to Check-in\n\n          8. use of any tobacco- or nicotine-containing products  within 6 months prior to\n             Check-in;\n\n          9. participation in any other investigational study drug trial within 30 days prior to\n             Check-in;\n\n         10. use of any prescription medications/products within 14 days prior to Check-in unless\n             deemed acceptable by the Investigator and Sponsor\n\n         11. use of any over-the-counter, nonprescription preparations within 7 days prior to\n             Check-in, unless deemed acceptable by the Investigator and Sponsor\n\n         12. use of alcohol-, grapefruit- (including star fruit), or caffeine-containing foods or\n             beverages within 72 hours prior to Check-in and through Study Completion\n\n         13. poor peripheral venous access;\n\n         14. donation of blood (500 mL) from 30 days prior to Screening through Study Completion\n\n         15. receipt of blood products within 2 months prior to Check-in;\n\n         16. any acute or chronic condition, scheduled hospitalization (inclusive of elective\n             surgery during study) or scheduled travel prior to completion of all study procedures\n             which, in the opinion of the Investigator, would limit the subject's ability to\n             complete and/or participate in this clinical study;\n\n         17. subjects who, in the opinion of the Investigator, should not participate in this\n             study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 5, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02080455", 
            "org_study_id": "AEGR-733-024"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Lomitapide & Atorvastatin - Taken Together", 
                    "Lomitapide & Atorvastatin - Approx. 12 hours between"
                ], 
                "description": "20 mg dose", 
                "intervention_name": "lomitapide", 
                "intervention_type": "Drug", 
                "other_name": "Juxtapid"
            }, 
            {
                "arm_group_label": [
                    "Lomitapide & Atorvastatin - Taken Together", 
                    "Lomitapide & Atorvastatin - Approx. 12 hours between"
                ], 
                "description": "80 mg", 
                "intervention_name": "Atorvastatin", 
                "intervention_type": "Drug", 
                "other_name": "Lipitor"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Atorvastatin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75247"
                }, 
                "name": "Covance Clinical Research Unit, Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Open-Label, Randomized, 2-Arm Study to Evaluate the Effect of Atorvastatin, a Weak CYP3A4 Inhibitor, on the Pharmacokinetics of Lomitapide in Healthy Subjects", 
        "overall_official": [
            {
                "affiliation": "Cheif Medical Officer", 
                "last_name": "Mark Sumeray, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Covance Clinical Research Unit Inc.", 
                "last_name": "T. Alex King, MD, CPI", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "area under the concentration-time curve from 0 to the last measurable concentration", 
            "measure": "AUC0-t", 
            "safety_issue": "No", 
            "time_frame": "predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02080455"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "time to maximum concentration", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing."
            }, 
            {
                "description": "time to maximum observed concentration", 
                "measure": "tmax", 
                "safety_issue": "No", 
                "time_frame": "Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing."
            }, 
            {
                "description": "apparent terminal elimination half-life", 
                "measure": "t1/2", 
                "safety_issue": "No", 
                "time_frame": "Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing."
            }, 
            {
                "description": "area under the concentration-time curve extrapolated to infinity", 
                "measure": "AUC0-\u221e", 
                "safety_issue": "No", 
                "time_frame": "Predose and at 1, 2, 3, 4, 5, 6, 8, 10, 12, 18, 24, 48, 72, 96, 120, 144, and 168 hours after dosing."
            }
        ], 
        "source": "Aegerion Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aegerion Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}